STATE OF NEW YORK

1316--A

2017-2018 Regular Sessions

IN SENATE

January 9, 2017

Introduced by Sens. LITTLE, KENNEDY, MARCHIONE, ORTT -- read twice and ordered printed, and when printed to be committed to the Committee on Insurance -- recommitted to the Committee on Insurance in accordance with Senate Rule 6, sec. 8 -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee

AN ACT to amend the insurance law, in relation to directing the New York state health care quality and cost containment commission to study and report upon the impact of requiring that certain health insurance plans provide coverage for treatment of mitochondrial disease

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Section 213 of the insurance law is amended by adding a new subsection (e) to read as follows:

(e) The commission shall cause a study to be performed on the impact of requiring certain health insurance plans to provide coverage for treatment of mitochondrial disease. Such study shall include an assessment of the impact of such a requirement on costs to providers, the cost of insurance premiums, and the fiscal impact to the state. The commission shall submit a report of the findings, conclusions and recommendation of such study, on or before November thirtieth, two thousand nineteen, to the governor, the temporary president of the senate, the speaker of the assembly, the chairs of the senate and assembly insurance committees, and the chairs of the senate and assembly health committees.

§ 2. This act shall take effect immediately.

EXPLANATION--Matter in *italics* (underscored) is new; matter in brackets [-] is old law to be omitted.

LBD00580-02-8